1. Introduction
===============

Primary small cell carcinoma (SCC) of the urinary tract is a rare cancer, accounting for less than 0.5% of urinary tract tumors,^\[[@R1]\]^ mostly localized in the bladder and prostate, while its localization in the renal pelvis or in the ureter is extremely rare. Smoking exposure causes reactive and genetic damage to the tissues, and is a main risk factor for urothelial carcinoma and small cell neuroendocrine carcinoma.^\[[@R2]\]^ Being such a rare disease, the pathogenesis is still unclear, and 2 theories have been postulated. The first claims its origin from a neuroendocrine cell population derived from the neural crest (enterochromaffin cells) migrated in the genitourinary tract during embryogenesis; the second theorizes its genesis from the pluripotent epithelial cells of the genitourinary tract. The latter could explain the common finding of a mixed histologic profile (transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcomatoid carcinoma, and sarcoma), often described as a gradual transition from 1 subtype to the other.

Small cell carcinoma of the ureter has been described in about 40 patients so far^\[[@R3]--[@R35]\]^ with similarities in symptoms, management, and outcome, as outlined in Table [1](#T1){ref-type="table"}.
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2. Case report
==============

A 79-year-old female presented with right-sided back pain and gross hematuria. Her clinical history was significant for atrial fibrillation treated with oral anticoagulant, which was suspended due to hematuria. She had a smoking history of more than 20 cigarettes per day for nearly 60 years. Physical examination revealed pain at the right costovertebral angle extended to the right groin over the location of the ureter. Creatinine levels at the admission were 1.37mg/dL. Abdominal ultrasound was immediately performed, revealing a grade 3 right hydronephrosis without lithiasis and hematic material in the bladder. A functional scintigraphy study with 99mTc-diethylene-triamine-penta-acetate revealed a decreased function of the right kidney, and the calculated glomerular filtration rate (GFR, Gates method) was 27 mL/min for the right kidney and 40 mL/min for the left kidney. At cystoscopic examination, the bladder wall was irregular in the right emitrigon, and the right ureteral orifice was swollen and bleeding. Urine cytology showed atypical morphological features, classified as suspicious for high-grade urothelial carcinoma (the Paris System for reporting urinary cytology). The following abdominal computed tomography (CT) scan found thickened walls in the distal part of the right ureter in the absence of lithiasis. A nephroureterectomy was planned, but had to be suspended due to the patient\'s clinical condition, and a segmental ureterectomy was performed instead. The right distal ureter was resected together with some enlarged regional nodes; its macroscopic inspection showed a thickened and hemorrhagic wall, with a nodular neoplasm of 2 × 1.5 cm obstructing the lumen and infiltrating the surrounding adipose tissue. The tumor was composed of small cell carcinoma admixed with infiltrating transitional cell carcinoma (Fig. [1](#F1){ref-type="fig"}). The neuroendocrine markers (synaptophysin, chromogranin-A, CD56) were positive in the SCC part of the tumor, the mitotic count was high, and the proliferative index counted by Ki-67 was more than 90%; the tumor was negative for vimentin and TTF-1. The final diagnosis was small cell neuroendocrine carcinoma invading 80% of the surgical specimen associated with high-grade urothelial carcinoma, both infiltrating the ureteral wall, the perineural spaces, and the perivisceral adipose tissue. The ureteral resection margins were negative. The right external iliac and presacral nodes were both metastatic for small cell neuroendocrine carcinoma. The pathological stage at the diagnosis was pT3N1 and the patient underwent a 2-week cycle of etoposide chemotherapy that had to be suspended for renal failure. The disease rapidly progressed: at 2 and a half months after admission and less than a month after segmental ureterectomy, an abdominal CT scan showed a contrast-enhanced 19 × 10 cm mass surrounding and obstructing the ureter, extended without clear margins to the aortocaval space, displacing the iliac vessels and infiltrating the surrounding tissues with diffuse pelvic lymphadenopathy. Chest and cranial CT scan did not detect any other lesions. The patient died for the progression of disease 5 months after admission.

![(A) Panoramic view of the ureteral tumor, hematoxylin--eosin stain (H&E). (B) The transitional cell carcinoma (red triangle) infiltrates the ureteral wall together with the small cell carcinoma (SCC) component with a clear lymphovascular invasion (black triangle) (H&E 10x). (C) The transitional cell carcinoma is intermixed with the SCC (H&E 20x). (D--F) The neuroendocrine markers are all positive in the SCC component (D: CD56, 10x; E: synaptophysin, 10x; F: chromogranin-A, 2x). (G) Ki-67 is remarkably high, especially in the SCC component of the tumor (2x). (H) TTF-1 immunohistochemistry is completely negative (2x). (I) The transitional cell carcinoma is CK7 positive (2x).](medi-97-e11113-g002){#F1}

3. Discussion
=============

The usual presentation is flank homolateral pain due to hydronephrosis (with or without irradiation to the groin) and gross hematuria due to the vascular invasion; less frequently the patient laments weight loss, dysuria, and urinary tract infection. When those symptoms appear, the disease might be already at late stages, also because the pain gradually increases over time, becoming chronic, allowing a differential diagnosis from lithiasis that presents as acute pain. Ultrasonography is the initial choice for imaging in a suspected obstruction of the urinary tract, helping the clinician to differentiate between lithiasis and other causes of obstruction; urography and CT scan are second-level procedures that allow to establish the presence of a mass, confirm an associated hydronephrosis due to the obstruction, and the extension of the tumor and the regional node status. Urine cytology can be a precious diagnostic tool, but it requires an expert cytologist to get the right diagnosis, considering the paucity of the neoplastic cells in the smear, the mixed histotypes, and the infrequency of small cell carcinoma. A CT-guided biopsy or a nephro-ureteral resection are the usual choices for the urologist, allowing a pathological diagnosis.

At gross examination, SCC is usually described as a firm greyish tumor, often with hemorrhagic areas, protruding and occluding the ureteral lumen, with ill-defined borders and with peritumoral wall thickening. Small cell carcinoma has an architecture similar to the neuroendocrine tumors of other sites, composed by solid sheets or different pattern such as rosette or nests, often associated with a desmoplastic reaction. Crush artefact ("Azzopardi effect") is common. The cells are small to medium-sized with scant cytoplasm and prominent nucleus with granular (classically described as "salt and pepper") chromatin. Mitosis and necrosis are frequent, and also vascular invasion. As previously mentioned, there may coexist other histological types such as squamous carcinoma, transitional carcinoma, adenocarcinoma, and sarcomatoid carcinoma. The differential diagnoses include poorly differentiated urothelial carcinoma, primitive neuroectodermal tumor, malignant lymphoma, lymphoepithelioma-like carcinoma, and plasmacytoid carcinoma, from which this tumor can be differentiated by immunohistochemistry.^\[[@R27]\]^ The neuroendocrine stains are usually positive (chromogranin A, synaptophysin, CD56, neuron-specific enolase) and it may show positivity for keratins such as cytokeratin (CK)7, epithelial membrane antigen, and pan-CK. Uroplakin III is usually negative, and this may help the differential diagnosis with transitional cell carcinoma. Vimentin expression has been previously related to a higher metastatic potential and a poor outcome in a clinical report.^\[[@R30]\]^ The tumor is frequently diagnosed at late stages, when it has already invaded the peri-uretheral tissues and the surrounding structures. The overall median survival is 17 months, with a 51.9% of 1-year survival rate.^\[[@R3]\]^ The primary treatment is surgical remotion of the tumor by ureterectomy or nephroureterectomy depending on the clinical status of the patient, stage, and localization of the tumor. Due to the aggressive course of SCC, the surgeon must address the radicality of the excision as early as possible, considering that in most cases the resection alone does not seem to stop the progression of the disease. If the clinical parameters of the patient are stable, the surgical treatment is usually followed by adjuvant chemotherapy and radiotherapy. It is important to note that the patient might be anemic for the long-term hematuria, and the obstruction caused by the tumor often causes hydronephrosis and impaired kidney function, so the clinical status of the patient might hinder a radical excision and/or an effective course of a systemic chemotherapy. There are promising reports about neoadjuvant chemotherapy, which has been used successfully to downstage the disease and lengthen the overall survival.^\[[@R10],[@R11],[@R36]\]^

4. Conclusions
==============

Small cell carcinoma of the ureter is an aggressive disease, and the factors that seem correlate with its prognosis are smoking history, age, male sex, tumor size, nodes, metastasis grading and size at diagnosis, the expression of vimentin, and incomplete resection. Although this is a rare tumor, effective targeted therapies are expected to be applied to improve the overall survival.
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